Quantcast
Home / Opinion / Letters to the Editor / Feds take steps to improve cancer care for Arizonans

Feds take steps to improve cancer care for Arizonans

Cancer cells - 3d rendered illustration

Cancer cells – 3d rendered illustration

If the past few weeks have shown us anything, it’s that America must maintain a robust health care system with a strong commitment to medical innovation. The federal government is rightfully focusing on the COVID-19 response for now, but there are other important medical treatment opportunities it can simultaneously pursue.

One of those innovative options is a cancer treatment known as CAR-T therapy. At International Cancer Advocacy Network, we have been greatly encouraged by the improvement shown by our patients who have been treated with CAR-T therapy. Many older Americans, however, may not have access to this promising treatment.

The Centers for Medicare and Medicaid Services, however, should be applauded for taking steps to expand access to care in this innovative field.

They did so by proposing a long-term solution that more appropriately reimburses the providers of these innovative treatments, which will ensure better access for seniors on Medicare with cancer and send a signal that America will continue to be the global leader when it comes to medical innovation.

Now, more than ever, it is important that we lay a strong foundation for medical innovation to continue in America. We are grateful the administration agrees on the issue of CAR-T.

Sidney M. Rosen is the founding chairman of International Cancer Advocacy Network, a 501(c)(3) nonprofit organization, headquartered in Phoenix, specializing in helping late-stage cancer patients find clinical trials and innovative therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

x

Check Also

Medicine background

Consumers, small businesses, taxpayers need relief from Big Pharma

According to a study conducted by Avik Roy and Gregg Girvan of the Foundation for Research on Equal Opportunity (FREOPP), Big Pharma’s abuse of the patent system around biologic drugs, such as Humira, cost American patients and taxpayers an additional $5 billion between 2015 and 2020. Without congressional action to hold brand name drug companies accountable, the report estimates this anti-competitive behavior around just this one class of drug will cost the American people another $25 billion by the end of the decade.

/* code for tag simpli.fi */